Content Talent Contest
Dear Colleague,
Content Ed Net is pleased to announce a Scientific Competition dedicated to clinicians, entitled
CLINICAL EXPERIENCE WITH LONCASTUXIMAB: SHARE YOUR CASE AND SHAPE THE FUTURE OF DLBCL TREATMENT
We would therefore be delighted if you would submit a research article describing a clinical case involving treatment with loncastuximab tesirine on label, in a patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
THE SUBMISSION DEADLINE FOR MANUSCRIPTS IS April 30th 2026.
As Guest Editor, I am confident that your contribution would provide valuable insight and add significant scientific merit to this initiative.
Kind regards,
Thomas Oellerich
Department of Medicine II Henatology/Oncology, University Hospital Frankfurt
INSTRUCTIONS FOR AUTHORS
Title
Complete, specific, and concise title that clearly reflects the content of the work, avoiding the use of abbreviations.
AUTHORS AND AFFILIATIONS
Authorship is limited to a maximum of two individuals. The first author must be a clinician
THE FIRST AUTHOR
The first author should be designated as the corresponding author. Their email address must be included on the manuscript’s title page.
For further information, please refer to the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals available at:
http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html.
Keywords
Five keywords identifying the subject of the manuscript must be provided.
Main Text
The Main Text should be approximately 1,000 words and structured as follows:
Case Report
This section should provide the case details in the following order: patient description; medical history; clinical examination findings; results of instrumental and other investigations; treatment plan; expected outcome of the treatment plan; actual outcome.
Discussion
This section should expand on the points made in the introduction, focusing on why the case is noteworthy and the clinical issue it addresses.
Conclusion
This section should briefly summarise the key points of the case report. The author may also provide practical suggestions or recommendations for colleagues within the context described.
Acknowledgements
All contributors who do not meet the criteria for authorship may be listed in the Acknowledgements section.
Disclosure and potential conflicts of interest
Authors must also disclose any potential conflicts of interest.
Additionally, they must confirm that informed consent was obtained from the patient, and the patient’s anonymity must be strictly maintained.
Funding
Any funding received to support the research must be disclosed.
AUTHOR Contribution
Authors should specify the individual contributions.
References
References must be formatted as:
Glare P, Aubrey K, Gulati A, Lee YC, Moryl N, Overton S. Pharmacologic management of persistent pain in cancer survivors.
Tables
Tables should be created using the table formatting and editing functions available in your word processing software (e.g., Microsoft Word).
Figures
If the figure is already available as a digital file in TIFF, EPS, or JPEG format, please submit the original file directly.
SUBMIT YOUR MANUSCRIPT
Please ensure that your manuscript adheres to the preparation
guidelines above, then send it via email to
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo. attaching your manuscript and all related figures.
In the subject line, please include: “Clinical Talent Contest – Loncastuximab- GERMANY”
Contest NEXT STEPS:
- EVALUATION – All submitted manuscripts will be reviewed by the Guest Editor and our editorial board.
- REVIEW – All manuscripts will undergo a peer-review process.
- SELECTION – The contest results will be communicated to all participants.
- PUBLICATION – The three best clinical cases, winners of the Contest, will contribute to a comprehensive review to be submitted to an international journal.
For any further information, please contact our editorial office at:
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.; and include in the subject line:
“Clinical Talent Contest – Loncastuximab- GERMANY”
With the non-conditional contribution of:
